Cargando…
COVID-19 et maladies bulleuses auto-immunes en 2022
The COVID-19 pandemic is evolving daily, forcing health authorities and physicians to continuously adapt. Patients with autoimmune bullous diseases (ABD), who are often elderly and/or immunocompromised, constitute a population at very high risk of developing a severe form. This study on the impact o...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Masson SAS.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847086/ http://dx.doi.org/10.1016/j.fander.2022.02.001 |
_version_ | 1784651973280137216 |
---|---|
author | Hébert, V. |
author_facet | Hébert, V. |
author_sort | Hébert, V. |
collection | PubMed |
description | The COVID-19 pandemic is evolving daily, forcing health authorities and physicians to continuously adapt. Patients with autoimmune bullous diseases (ABD), who are often elderly and/or immunocompromised, constitute a population at very high risk of developing a severe form. This study on the impact of COVID-19 on patients with ABD has brought out several key messages: (i) the prescription of rituximab is associated with an increased risk of mortality, contrary to conventional immunosuppressants; (ii) rituximab should only be prescribed for patients in flare-up of their disease, in the absence of any therapeutic alternative; (iii) vaccination of patients and their entourage is still the best solution for reducing the risk of progression to a severe form. |
format | Online Article Text |
id | pubmed-8847086 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Masson SAS. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88470862022-02-16 COVID-19 et maladies bulleuses auto-immunes en 2022 Hébert, V. Annales de Dermatologie et de Vénéréologie - FMC Mise Au Point The COVID-19 pandemic is evolving daily, forcing health authorities and physicians to continuously adapt. Patients with autoimmune bullous diseases (ABD), who are often elderly and/or immunocompromised, constitute a population at very high risk of developing a severe form. This study on the impact of COVID-19 on patients with ABD has brought out several key messages: (i) the prescription of rituximab is associated with an increased risk of mortality, contrary to conventional immunosuppressants; (ii) rituximab should only be prescribed for patients in flare-up of their disease, in the absence of any therapeutic alternative; (iii) vaccination of patients and their entourage is still the best solution for reducing the risk of progression to a severe form. Elsevier Masson SAS. 2022-04 2022-02-16 /pmc/articles/PMC8847086/ http://dx.doi.org/10.1016/j.fander.2022.02.001 Text en © 2022 Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Mise Au Point Hébert, V. COVID-19 et maladies bulleuses auto-immunes en 2022 |
title | COVID-19 et maladies bulleuses auto-immunes en 2022 |
title_full | COVID-19 et maladies bulleuses auto-immunes en 2022 |
title_fullStr | COVID-19 et maladies bulleuses auto-immunes en 2022 |
title_full_unstemmed | COVID-19 et maladies bulleuses auto-immunes en 2022 |
title_short | COVID-19 et maladies bulleuses auto-immunes en 2022 |
title_sort | covid-19 et maladies bulleuses auto-immunes en 2022 |
topic | Mise Au Point |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847086/ http://dx.doi.org/10.1016/j.fander.2022.02.001 |
work_keys_str_mv | AT hebertv covid19etmaladiesbulleusesautoimmunesen2022 |